keine Finanzberatung

BSX · Boston Scientific Corp.

Medical devices — cardiology, endoscopy, neuromodulation

Risiko 5/10 · MODERATE RISK · medtech in a growth stall · $47.80 ▲ 1.81%Von KI geschrieben

Stand der Zahlen: · Quellen: öffentliche Markt-Aggregatoren

Kennzahlen

  • Price $47.80
  • Market cap $69.3B
  • P/E (ttm) 19.35
  • Div yield none
  • 52-wk range $42.20 – $109.50
  • Index rank #189 / —

Wichtigste Risiken

  • Growth slowdown in core franchises proves structural (Shareholders) — HIGH
  • Further de-rating as momentum holders exit (Shareholders) — HIGH
  • Device recall or product-liability litigation (Customers) — MED
  • Serial-acquisition integration missteps (Shareholders) — MED

Fazit

Cheap versus its own history, but only if the growth stall proves temporary — wait for evidence, not hope.

Interaktive Analyse öffnen →

Recherche, keine Anlageberatung.

⚠️ Independent research for a video, not financial advice. Figures from public sources/aggregators, can be stale; risk scores are editorial estimates. Verify before relying on any of it.